Dr. Saltzstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
18915 Meisner Dr
San Antonio, TX 78258Phone+1 210-499-5158Fax+1 210-679-3730
Education & Training
University of Texas Medical Branch HospitalsResidency, Urology, 1986 - 1992
The University of Texas Health Science Center at San AntonioClass of 1986
Certifications & Licensure
TX State Medical License 1987 - 2025- American Board of Urology Urology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer Start of enrollment: 2007 Apr 01
- Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance Start of enrollment: 2014 May 08
- Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery Start of enrollment: 2014 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Apalutamide for High-Risk Localized Prostate Cancer Following Radical Prostatectomy (Apa-RP).Neal Shore, Jason Hafron, Daniel Saltzstein, Gordon Brown, Laurence Belkoff
The Journal of Urology. 2024-11-01 - Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery.Tracy M Downs, Howard H Bailey, Taja Lozar, Natalie S Schmitz, Heather Green
Cancer Prevention Research. 2024-08-27 - 5 citationsTestosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study.Ronald Tutrone, Fred Saad, Daniel J George, Bertrand Tombal, James L Bailen
European Urology Oncology. 2024-08-01
Press Mentions
Challenges Persist in Deploying ADT in Prostate CancerJanuary 11th, 2017- Triggers to Initiate Androgen-Deprivation Therapy (ADT) in Prostate CancerNovember 30th, 2016
Expert Panel Highlights State of the Art and Next Steps in Bladder Cancer ParadigmNovember 4th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
